Imagine waiting years for a diagnosis for your child, only to be told the cutting-edge treatment is just out of reach because of slow government approvals. That’s the heartbreaking reality many families face, and it’s why a new law in Montana, called the "right to try" law, is getting a lot of attention.
This story revolves around Kris DeVault and his son, Brody, who started missing key developmental milestones like speech and movement around two and a half years old. After countless tests, they finally got a diagnosis: a rare genetic condition called DARS. This condition is incredibly serious, causing a progressive loss of brain function, and doctors told Kris that Brody likely wouldn't live past the age of five.
The good news is, there's a potential treatment. Researchers at a company called GeneTx Biotherapeutics developed an experimental gene therapy that could slow or even stop the progression of DARS. The bad news? This therapy is still going through the lengthy approval process with the Food and Drug Administration (FDA) [the government agency that ensures new drugs are safe and effective]. This process can take years, and for children like Brody, time is a luxury they don't have.
This is where Montana's new "right to try" law comes in. It lets patients with life-threatening conditions try experimental treatments that haven't yet received full FDA approval, provided certain conditions are met. Think of it like this: if you have a leaky roof and your house is flooding, a "right to try" law would let you use a new, unproven patching material that a trusted expert has designed, instead of waiting for the government to fully test and certify it for every type of roof. It’s a way to access promising options when standard ones aren't enough.
While this specific case doesn't involve AI directly, it highlights a broader pattern we’re seeing: the tension between the speed of scientific advancement and the pace of regulatory oversight. As AI increasingly plays a role in drug discovery and personalized medicine, we might see similar "right to try" discussions emerge around AI-driven diagnostics or therapies. These laws aim to bridge the gap for patients who don’t have time to wait for the traditional, often slow, approval pipelines.
For the DeVault family, this law offers a glimmer of hope. Kris DeVault believes it could be the only chance to save his son's life. He and other families are pushing for quicker access to these experimental treatments, arguing that when facing a terminal illness, the benefits of trying a potentially life-saving therapy outweigh the risks of waiting.
"Right to try" laws aim to provide a faster path to experimental treatments for patients with life-threatening conditions, balancing urgent need with regulatory caution.